Comprehensive Stock Comparison
Compare Unicycive Therapeutics, Inc. (UNCY) vs Amarin Corporation plc (AMRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AMRN | -25.5% revenue growth vs UNCY's -100.0% |
| Stability / Safety | UNCY | Beta 0.81 vs AMRN's 0.84 |
| Dividends | UNCY | 2.4% yield; 1-year raise streak; AMRN pays no meaningful dividend |
| Momentum (1Y) | AMRN | +27.3% vs UNCY's +26.0% |
| Efficiency (ROA) | AMRN | -13.1% ROA vs UNCY's -66.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — while advancing its lead candidates through clinical trials. The company's competitive advantage lies in its specialized focus on kidney disease therapeutics and proprietary drug development platforms targeting unmet medical needs in nephrology.
Amarin Corporation is a pharmaceutical company focused on developing and commercializing cardiovascular therapeutics. It generates nearly all its revenue from VASCEPA — a prescription omega-3 fatty acid product for reducing triglyceride levels — sold primarily to wholesalers and specialty pharmacies. Its key advantage is patent protection and regulatory exclusivity for VASCEPA, though this moat faces challenges from generic competition.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AMRN leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). UNCY leads in 1 (Total Returns). 1 tied.
Financial Metrics (TTM)
AMRN and UNCY operate at a comparable scale, with $227M and $0 in trailing revenue.
| Metric | UNCYUnicycive Therape… | AMRNAmarin Corporatio… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $227M |
| EBITDAEarnings before interest/tax | -$31M | -$93M |
| Net IncomeAfter-tax profit | -$33M | -$86M |
| Free Cash FlowCash after capex | -$30M | -$22M |
| Gross MarginGross profit ÷ Revenue | — | +38.9% |
| Operating MarginEBIT ÷ Revenue | — | -42.5% |
| Net MarginNet income ÷ Revenue | — | -38.0% |
| FCF MarginFCF ÷ Revenue | — | -9.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +28.3% | +69.7% |
Valuation Metrics
| Metric | UNCYUnicycive Therape… | AMRNAmarin Corporatio… |
|---|---|---|
| Market CapShares × price | $144M | $5.7B |
| Enterprise ValueMkt cap + debt − cash | $119M | $5.6B |
| Trailing P/EPrice ÷ TTM EPS | -1.24x | -3.45x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.01x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 25.11x |
| Price / BookPrice ÷ Book value/share | 6.25x | 0.58x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AMRN delivers a -18.8% return on equity — every $100 of shareholder capital generates $-19 in annual profit, vs $-89 for UNCY. AMRN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to UNCY's 0.10x. On the Piotroski fundamental quality scale (0–9), UNCY scores 4/9 vs AMRN's 2/9, reflecting mixed financial health.
| Metric | UNCYUnicycive Therape… | AMRNAmarin Corporatio… |
|---|---|---|
| ROE (TTM)Return on equity | -89.1% | -18.8% |
| ROA (TTM)Return on assets | -66.0% | -13.1% |
| ROICReturn on invested capital | — | -18.7% |
| ROCEReturn on capital employed | -15.3% | -17.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.10x | 0.02x |
| Net DebtTotal debt minus cash | -$25M | -$113M |
| Cash & Equiv.Liquid assets | $26M | $121M |
| Total DebtShort + long-term debt | $773,000 | $8M |
| Interest CoverageEBIT ÷ Interest expense | -335.02x | -7085.14x |
Total Returns (with DRIP)
A $10,000 investment in UNCY five years ago would be worth $1,386 today (with dividends reinvested), compared to $1,115 for AMRN. Over the past 12 months, AMRN leads with a +27.3% total return vs UNCY's +26.0%. The 3-year compound annual growth rate (CAGR) favors UNCY at 10.3% vs AMRN's -30.2% — a key indicator of consistent wealth creation.
| Metric | UNCYUnicycive Therape… | AMRNAmarin Corporatio… |
|---|---|---|
| YTD ReturnYear-to-date | +19.5% | +0.6% |
| 1-Year ReturnPast 12 months | +26.0% | +27.3% |
| 3-Year ReturnCumulative with dividends | +34.0% | -66.0% |
| 5-Year ReturnCumulative with dividends | -86.1% | -88.9% |
| 10-Year ReturnCumulative with dividends | -86.1% | -52.7% |
| CAGR (3Y)Annualised 3-year return | +10.3% | -30.2% |
Risk & Volatility
UNCY is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than AMRN's 0.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMRN currently trades 66.0% from its 52-week high vs UNCY's 63.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | UNCYUnicycive Therape… | AMRNAmarin Corporatio… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 0.84x |
| 52-Week HighHighest price in past year | $11.00 | $20.90 |
| 52-Week LowLowest price in past year | $3.71 | $7.08 |
| % of 52W HighCurrent price vs 52-week peak | +63.0% | +66.0% |
| RSI (14)Momentum oscillator 0–100 | 56.2 | 40.0 |
| Avg Volume (50D)Average daily shares traded | 474K | 76K |
Analyst Outlook
Wall Street rates UNCY as "Buy" and AMRN as "Hold". UNCY is the only dividend payer here at 2.36% yield — a key consideration for income-focused portfolios.
| Metric | UNCYUnicycive Therape… | AMRNAmarin Corporatio… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | — | $2.17 |
| # AnalystsCovering analysts | 5 | 18 |
| Dividend YieldAnnual dividend ÷ price | +2.4% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.16 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 21 | Feb 26 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | 100 | 12.9 | -87.1% |
| Amarin Corporation … (AMRN) | 100 | 17.77 | -82.2% |
Unicycive Therapeut… (UNCY) returned -86% over 5 years vs Amarin Corporation … (AMRN)'s -89%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | $0.00 | $0.00 | — |
| Amarin Corporation … (AMRN) | $82M | $229M | +179.6% |
Amarin Corporation plc's revenue grew from $82M (2015) to $229M (2024) — a 12.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | -19.0% | -45.3% | -138.3% |
| Amarin Corporation … (AMRN) | -140.9% | -35.9% | +74.5% |
Amarin Corporation plc's net margin went from -141% (2015) to -36% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | -0.14 | -5.6 | -3900.0% |
| Amarin Corporation … (AMRN) | -16.6 | -4 | +75.9% |
Amarin Corporation plc's EPS grew from $-16.60 (2015) to $-4.00 (2024).
Chart 5Free Cash Flow — 5 Years
Unicycive Therapeutics, Inc. generated $-29M FCF in 2024 (-394% vs 2021). Amarin Corporation plc generated $-31M FCF in 2024 (+53% vs 2021).
UNCY vs AMRN: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is UNCY or AMRN a better buy right now?
Analysts rate Unicycive Therapeutics, Inc. (UNCY) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — UNCY or AMRN?
Over the past 5 years, Unicycive Therapeutics, Inc. (UNCY) delivered a total return of -86.1%, compared to -88.9% for Amarin Corporation plc (AMRN). A $10,000 investment in UNCY five years ago would be worth approximately $1K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AMRN returned -52.7% versus UNCY's -86.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — UNCY or AMRN?
By beta (market sensitivity over 5 years), Unicycive Therapeutics, Inc. (UNCY) is the lower-risk stock at 0.81β versus Amarin Corporation plc's 0.84β — meaning AMRN is approximately 4% more volatile than UNCY relative to the S&P 500. On balance sheet safety, Amarin Corporation plc (AMRN) carries a lower debt/equity ratio of 2% versus 10% for Unicycive Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — UNCY or AMRN?
Unicycive Therapeutics, Inc. (UNCY) is the more profitable company, earning 0.0% net margin versus -35.9% for Amarin Corporation plc — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNCY leads at 0.0% versus -40.2% for AMRN. At the gross margin level — before operating expenses — AMRN leads at 35.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — UNCY or AMRN?
In this comparison, UNCY (2.4% yield) pays a dividend. AMRN does not pay a meaningful dividend and should not be held primarily for income.
06Is UNCY or AMRN better for a retirement portfolio?
For long-horizon retirement investors, Unicycive Therapeutics, Inc. (UNCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.81), 2.4% yield). Both have compounded well over 10 years (UNCY: -86.1%, AMRN: -52.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between UNCY and AMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. UNCY pays a dividend while AMRN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.